Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C

  • Technology appraisal guidance
  • TA75
  • Published: 
  • Last updated: 

Review decision, August 2008

Review of NICE Technology Appraisal Guidance Nos 75 & 106 Hepatitis C – peginterferon alpha and ribavirin (mild and moderate)

Review decision

The Institute was proposing that we schedule the review into the technology appraisals work programme, including relevant licensing extensions.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. The Institute?s Guidance Executive has decided to proceed with the proposal. The appraisal is expected to start in approximately early April 2009 .

A summary of the responses from this consultation can be found below.

7 August 2008

This page was last updated: 02 January 2011